View Older Stories View More Recent Stories
-
Celcuity Inc. Announces $100 Million Private Placement
-
Achilles Therapeutics (ACHL) Appoints Bernhard Ehmer to its Board
-
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
-
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
-
Avilar Therapeutics Executives to be Featured Speakers on Advances in Protein Degradation at Upcoming Drug Discovery Conferences
-
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
-
Form SC 13D/A Nkarta, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
-
DTx Pharma Announces Appointment of Kathie M. Bishop to its Board of Directors
-
Form SC 13G NanoString Technologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G VERU INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Avilar Therapeutics to Present Scientific Poster on ATACs, a New Class of Degraders for Targeting Extracellular Proteins, at Protein Degradation Conference
-
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
-
CDR-Life Announces $76 Million Raised in Series A Funding
-
Jeito Capital Co-Leads $76 Million Series A Financing for CDR-Life, its 10th Investment Since its Launch
-
Adcendo presents Data on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
-
Form SC 13G AN2 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
-
PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
-
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
-
Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
-
RA Capital Management Pivots to Metaverse Medicines
-
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
-
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
-
PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
-
Form SC 13G FLUIDIGM CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer
-
PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Avilar Therapeutics to Present at the Guggenheim Targeted Protein Degrader Day
-
Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller
-
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
-
Form SC 13D/A Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Selux Diagnostics Announces Additional $50 Million in Series C Funding
-
Form SC 13G Vera Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Somatus Raises $325M to Deliver Proven Value-Based Kidney Care Model to More Americans with Kidney Disease
-
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
-
Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-phase Research to the Clinic
-
Form SC 13G/A Kinnate Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ChemoCentryx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ImmunoGen, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Seres Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A CONCERT PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
